Frankfurt
31.10.25 | 08:02
1,324 Euro
-0,15 % -0,002
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,406 | 1,470 | 19:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | Saniona AB: Saniona publishes its interim report for the second quarter of 2025 | 163 | GlobeNewswire (Europe) | Three Months Ended June 30, 2025 (2024)Six Months Ended June 30, 2025 (2024)Revenue was SEK 9.3 M (8.0 M)Revenue was SEK 19.1 M (14.1 M)Operating profit/loss was SEK -25.9 M (-16.0 M)Operating profit/loss... ► Artikel lesen | |
| 21.08. | JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug | 1 | Zacks | ||
| SANIONA Aktie jetzt für 0€ handeln | |||||
| 21.08. | Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug | 3 | MedCity News | ||
| 20.08. | Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement | 2 | Contract Pharma | ||
| 20.08. | Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble | 3 | FierceBiotech | ||
| 20.08. | Jazz Pharmaceuticals enters exclusive licensing deal with Saniona | 5 | Seeking Alpha | ||
| 20.08. | Jazz pharmaceuticals acquires rights to Saniona's epilepsy drug candidate | 2 | Investing.com | ||
| 20.08. | Saniona AB: Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Develop and Commercialize SAN2355 | 242 | GlobeNewswire (Europe) | Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Jazz obtains exclusive worldwide rights to... ► Artikel lesen | |
| 28.05. | Saniona AB: Bulletin from the Saniona AB annual shareholders' meeting on May 28, 2025 | 174 | GlobeNewswire (Europe) | Today, on May 28, 2025, the annual shareholders' meeting was held in Saniona AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and distribution of the company's... ► Artikel lesen | |
| 12.05. | Saniona AB: Saniona appoints Johnny Stilou as Chief Financial Officer | 200 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Johnny Stilou as Chief Financial Officer, effective immediately. He brings more than 25 years of... ► Artikel lesen | |
| 10.04. | Saniona - Broad pipeline to address neurological conditions | 430 | Edison Investment Research | Saniona is a European pioneer in ion channel drug discovery. Internally, it is primarily focused on its preclinical epilepsy pipeline: SAN2355 (for focal/generalised epilepsy) and SAN2219 (for acute... ► Artikel lesen | |
| 26.03. | Saniona AB: Saniona initiates scale-up and manufacturing of toxicology batches for SAN2219, a potential new therapy for epilepsy | 542 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the initiation of scale-up and manufacturing of toxicology batches for SAN2219, advancing the program toward clinical... ► Artikel lesen | |
| 11.03. | Saniona AB: Saniona and Boehringer Ingelheim extend research collaboration with one year | 532 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year.
"The... ► Artikel lesen | |
| 10.03. | Saniona AB: Saniona Appoints Pierandrea Muglia, M.D., as Chief Medical Officer | 177 | GlobeNewswire (Europe) | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experience... ► Artikel lesen | |
| 03.03. | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | 437 | Business Wire | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| 27.02. | Saniona AB: Saniona publishes its year-end report for 2024 | 203 | GlobeNewswire (Europe) | Three Months Ended December 31, 2024 (2023)Twelve Months Ended December 31, 2024 (2023)Revenue was SEK 313.4 M (5.4 M)Revenue was SEK 334.7 M (16.8 M)Operating profit/loss was SEK 290.4 M (-19.8 M)Operating... ► Artikel lesen | |
| 28.11.24 | Saniona AB: Saniona publishes its interim report for the third quarter of 2024 | 239 | GlobeNewswire (Europe) | Three Months Ended September 30, 2024 (2023)Nine Months Ended September 30, 2024 (2023)Revenue was SEK 7.2 M (5.5 M)Revenue was SEK 21.3 M (11.5 M)Operating profit/loss was SEK -18.9 M (-18.4 M)Operating... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| NANOREPRO | 1,685 | -0,88 % | EQS-News: NanoRepro AG: Halbjahreszahlen 2025 - NanoRepro setzt Wachstumskurs fort | EQS-News: NanoRepro AG
/ Schlagwort(e): Halbjahresbericht
NanoRepro AG: Halbjahreszahlen 2025 - NanoRepro setzt Wachstumskurs fort
31.10.2025 / 12:00 CET/CEST
Für den... ► Artikel lesen | |
| 4SC | 0,680 | +3,66 % | 4SC AG ringt um Zukunft nach schwerem Rückschlag | Das Biotech-Unternehmen 4SC AG (ISIN: DE000A3E5C40) aus Planegg-Martinsried steht an einem kritischen Wendepunkt. Nachdem die Europäische Arzneimittelbehörde EMA im Mai die Zulassung für das Krebsmedikament... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| BRAIN BIOTECH | 2,170 | -1,36 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| AAP IMPLANTATE | 1,410 | -4,08 % | EQS-News: aap Implantate AG mit starkem Wachstum in Q3/2025: +15% | EQS-News: aap Implantate AG
/ Schlagwort(e): 9-Monatszahlen
aap Implantate AG mit starkem Wachstum in Q3/2025: +15%
28.10.2025 / 08:00 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIOXXMED | 0,120 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur ordentlichen Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| CLINUVEL | 6,430 | -1,00 % | Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy | Original-Research: CLINUVEL Pharmaceuticals Limited - from Parmantier & Cie. GmbH
30.09.2025 / 10:52 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,517 | -1,45 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call | ||
| BIO-GATE | 0,775 | 0,00 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate beschließt und platziert Barkapitalerhöhung | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalerhöhung/Sonstiges
Bio-Gate AG beschließt und platziert Barkapitalerhöhung
29.10.2025 / 18:39 CET/CEST
Veröffentlichung einer Adhoc-Mitteilung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,140 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| EDITAS MEDICINE | 2,717 | +1,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| EXELIXIS | 33,280 | -0,78 % | Exelixis Q2 2025: Cabozantinib-Franchise wächst um 19 %, Markteinführung bei NET gewinnt an Fahrt |
Das Unternehmen SANIONA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,15 % bei einem Aktienkurs von 1,324 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANIONA AB finden Sie auf Wallstreet Online.